Cubist patent invalidation: a very tough start to a relatively sound strategic deal of Merck
U.S. District Judge Gregory Sleet in D. Del. [ Wilmington, Delaware], ruled Dec. 8. that claims of four patents of Cubist Pharma are invalid. Cubist is being bought by Merck & Co. (MRK) for $8.4 billion.
Looking at the court filings, one might infer that Monday's outcome was foreseeable.